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1.   INTRODUCTION
           Although surgeons  and gastroenterologists  have used diagnostic 
laparoscopy  since  the  early  1900s,  today's  surgical  oncologists  have  been 
relatively  slow  to  embrace  this  technology.  Together  with  the  fervor  and 
benefits afforded by laparoscopic therapeutic interventions in the management 
of patients with benign disease and the diagnostic usefulness in blunt trauma 
and abdominal pain, awareness has been rekindled regarding the advantages of 
laparoscopy  for  the  staging  of  abdominal  malignancy.  The  morbidity  and 
mortality of exploratory laparotomy with unresectable tumors has been from 
13 to 23% and 10 to 21% respectively42. As surgeons begin to realize that 
extirpative procedures are doomed to failure in curing patients with diffuse 
abdominal metastases disclosed on laparoscopic assessment, palliative 
measures, such as stent placement, ablative procedures, balloon dilatation, 
intraluminal high-dose radiation, and laser techniques will be used commonly 
by surgical endoscopists and gastroenterologists. Similarly, it is hoped that the 
use of systemic chemotherapy will achieve better specificity in cell destruction 
in patients identified laparoscopically to have uncontained  disease in the 
abdominal cavity. The sensitivity of imaging combined with laparoscopy has 
been shown to approach that of celiotomy in the evaluation of solid organs, 
thereby avoiding unnecessary laparotomy and its associated morbidities. Using 
imaging as a complement to laparoscopy will  extend the usefulness of both 
techniques.  The  application  of  laparoscopy  and  the  advent  of  miniaturized 
laparoscopic  instrumentation,  both  diagnostic  and  therapeutic,  in  the 
management of patients with abdominal malignancy will be limited only by the 
creativity and expertise of physicians and instrument makers.
          Accurate cancer diagnosis and staging are crucial to the determination of  
an  efficacious  treatment  plan  for  localized  and  advanced  malignancy.  The 
physician  must  differentiate  patients  with  potentially  resectable,  localized 
disease from those with advanced and /or distant disease. The diagnostic and 
staging modalities currently available are expensive and often inaccurate. This 
can  result  in  the  nonoperative  management  of  potentially  resectable 
malignancies or,  more commonly,  in an underestimation of the preoperative 
cancer stage with intraoperative evidence of advanced / metastatic disease. The 
combination of laparoscopy and laparoscopic ultrasonography can be used to 
help diagnose and stage malignancies and select patients for either curative or 
palliative procedures.
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          The role of laparoscopy in the care of patients with cancer is currently 
evolving.  Numerous  experimental  and  clinical  studies  have  attempted  to 
elucidate the nature and cause of port-site metastases, particularly to discern  
whether they simply are a marker of advanced disease, or if they are a result of  
the  laparoscopic  intervention.  Laparoscopy  has  a  role  in  establishing  the 
diagnosis of cancer in some situations by allowing biopsy of intraperitoneal and 
retroperitoneal masses, lymph nodes, peritoneal and visceral lesions, as well as 
examination  of  abdominal  contents  under  direct  vision  or  with  ultrasound 
probes. Laparoscopy also has a role in the surgical treatment of a variety of 
malignancies  including  gastric  carcinoma,  pancreatic  cancer,  splenic 
malignancies, adrenal cancers, and colon cancer. Lastly, laparoscopy can play 
an  important  role  in  the  palliative  care  of  the  cancer  patient  in  performing 
procedures such as feeding-tube placement or intestinal stoma creation. It  is  
imperative that using laparoscopy in the care of patients with malignancies is 
carefully and thoroughly evaluated since this technique can either benefit  or 
adversely affect survival or quality of life.
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2.   AIM
          
           The aim of the present study were to evaluate the relative benefit of the 
‘pretreatment / diagnostic laparoscopy’ in selective patients of intra-abdominal 
malignancy  for  identifying  occult  surface  metastasis  and  locally  invasive 
lesions,  thereby reducing unnecessary /  nontherapeutic  laparotomy and their 
associated morbidity and mortality. The present imaging (USG, CT-scan, MRI) 
fails to identify all the metastasis and local invasion lesions [see 
figures – 1 to 4 ] especially when metastasis are below 1 cm. in size.
          The other aims of the present study was also to assess the diagnostic  
value  of  laparoscopy  compared   to  imaging  (US,  CT,  MRI)   in   detecting 
intra-abdominal  metastatic  spread.  The  major  advantage  of  diagnostic 
laparoscopy  for  patients  with  a  gastrointestinal  tumor  is  the  prevention  of 
unnecessary  explorative  laparotomy.  However,  it  is  doubtful  whether  this 
procedure  also  prevents  late  laparotomy  that  are  necessary  for  palliative 
treatment  during  follow-up.  Staging  laparoscopy  should  be  performed  to 
identify  patients  with  liver  or  peritoneal  metastases  who  have  an  expected 
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survival of approximately 3 to 9 months14, 29,32,39,46,63, in whom minimally
  
                        
Fig: 1 CT Scan - Hepatocellular carcinoma
  
                            Fig: 2 CT Scan - Gall-bladder carcinoma
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Fig: 3 CT Scan-Pancreatic head carcinoma
Fig: 4 MRI Scan-Pancreatic head carcinoma
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 invasive palliation will be satisfactory.          
           Before the era of laparoscopy all  patients suspected of abdominal 
malignancy  undertook  explorative  laparotomy.  Only  a  minority  (10  to 
30%)14,29,32,39,46,63 had  curative  or  palliative  surgery  and  the  rest  suffered  the 
morbidity and mortality of the nontherapeutic laparotomy. With the inventions 
of  glass-rod  optic  (telescope)  and  Veress  needle  more  patients  are  having 
minimally invasive evaluation. On this basis, we studied the usefulness of the 
preliminary / diagnostic laparoscopy in avoiding unnecessary / nontherapeutic 
laparotomy. 
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3. MATERIALS & METHODS
           The  present  study  was  done  in  the  Department  of  Surgical  
Gastroenterology, Madras Medical College, Chennai-3, from September 2003 
to October 2005 in a series of 60 patients of which 40 males, 20 females and 
age varied from 35 to 77 years ( Fig.: 15 & 16 ). 
            The pretreatment laparoscopy were performed in selective patients with 
intra-abdominal  malignancy  in  order  to  accurately  stage  their  lesions  and 
ascertain resectability.  Patients in whom conventional imaging had disclosed 
obviously  unresectable  lesions  (i.e.  ascites,  pelvic  deposits,  distant 
lymphadenopathy, liver metastases) were excluded from present study. Patients 
with  comorbid  diseases,  complications  requiring  open  palliative  bypass 
procedures were also excluded from this study.
           All  laparoscopy  was  performed  under  general  anesthesia  with 
intermittent  positive-pressure  ventilation.  The  site  for  the  CO2 
pneumoperitoneum needle and trocar were selected, when possible, below the 
umbilicus and insufflated until the intra-abdominal pressure reached 8 to 10 
mmHg (4 to 5 liters of CO2). Both 0° forward-viewing and 30° side-viewing 
5mm  telescopes  were  used.  The  visible  surfaces  of  the  liver,  diaphragm, 
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omentum,  visceral  and  parietal  peritoneum  were  carefully  examined  for 
evidence of malignant deposits and ascites. Most of the anterior wall of the 
stomach,  anterior-inferior  liver  surface,  anterior  parietal  peritoneum,  and 
anterior  surface  of  omentum  could  be  inspected  without  manipulation. 
However, a second puncture to the lateral of the midline permitted introduction 
of a probe with which the viscera could be moved so as to determine the extent  
of  infiltration  of  the  primary lesion and invasion of  the  adjacent  structures 
(See Fig. 7). Inserting the laparoscope through a small opening at the gastro-
colic or gastro-hepatic omentum facilitated inspection of the lesser sac. Areas 
infiltrated  by tumor  feel  hard  and  fixed.  Combined  inspection  and  probing 
provide a fairly accurate estimate of the extent of disease. By elevating the left 
lobe of the liver with the probe, the undersurface can be inspected by means of 
the side-viewing telescope for evidence of metastases. Rotating the telescope 
by 180° brings into view the lesser curve of the stomach, lesser omentum and 
the caudate lobe of the liver.
         If the patient is not obese, the anterior surface of the pancreas can be seen  
through  the  translucent  gastro-hepatic  omentum.  Infiltration  by  tumor  is 
reflected  in  neovascularization  and  loss  of  its  normal  smooth,  glistening 
appearance. Inspection and manipulation are aided by elevating the head-end of  
the table. The pelvic cavity is examined by elevating the foot-end of the table.  
Guided-biopsy  were  performed(see  Fig.16),  with  proper  caution,  including 
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tissue from the mass,  parietal  peritoneum, omentum and nodes but deferred 
until inspection and probing is complete, as blood trickling from a biopsy site 
may hamper proper visualization. The ascitic fluid and peritoneal lavage fluid 
were taken for cytological studies in few patients (100ml of normal saline was 
instilled into the sub-phrenic space, pelvic cavity and 20ml of lavage fluid were 
recovered for cytologic evaluation). In the present study the procedure were 
accomplished in about 15 to 45 minutes. Patients found to be laparoscopically 
operable underwent laparotomy.
         Strict observation of the patients in the postoperative ward was done and 
all the complications were treated. Patients were either referred or discharged 
between 2 to10 days.
         Patient demographics, preoperative imaging, laparoscopy findings and 
postoperative course were analyzed. Postoperative complications were scored 
by  ‘Memorial  Sloan-Kettering  cancer  center  grading  system’,  which  ranks 
complications according to severity as follows: 
1) Requiring oral antibiotics or bedside management such as local wound 
care; 
2) Requiring intravenous treatment; 
3) Requiring operative or radiological intervention;
4) Resulting in significant chronic disability; and 
5) Resulting in death as a result of the complication.
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Statistical analysis: 
           The ‘Sensitivity’ is expressed as the ratio of the true-positive to all of 
those with the diseases  [true-positive /  (true-positive + false-negative)].  The 
‘Specificity’ is  expressed as  the  ratio  of   true-negative  to  all  those  without 
diseases  [True-negative  /  (true-negative  +  false  positive)].  The  ‘Positive 
predictive value’ is the ratio of true disease positive to all positive test [true-
positive / (true-positive + false-positive)] and the ‘Negative predictive value’ is  
the ratio of the true-negative to all negative test [true-negative / (true-negative + 
false-negative)]. The ‘Accuracy’ of laparoscopy was calculated by dividing the 
number of patients found to be inoperable at laparoscopy by the total number of  
patients found to be inoperable. The ‘Yield’ of laparoscopy was defined as the 
number of patients spared a laparotomy divided by the total number of patients 
in this study.
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4.   OBSERVATIONS AND RESULTS
         
              In this study of 60 patients, there were 40 men and 20 women, with 
mean age of 53.2 years (range 35 to 77). Cancers involving proximal stomach 
were seen in 21 patients(35%), pancreas in 18 patients(30%), liver in 10 
(16.6%) patients and gall-bladder in 11 (18.3%) patients.
Table 1: Laparoscopy.
Organ No(%)
60
L
2
3
P
1
2
A
5
I
11
M1/Adv
37(61.6%)
Bx
6/37
(16.2%)
Cy
15/37
(40.5%)
Compl
6/37
(16.2%)
1
.
PGC/OGJ 21(35) 2 5 4 9 10(47.6) 4 6 3
2
.
Panc. 18(30) 4 4 1 - 8(44.4) 2 5 2
3
.
Liver 10(16.6) 1
0
- - - 10(100) - - -
4
.
Gallbl. 11(18.3) 7 3 - 2 9(81.8) - 4 1
# L-Liver, P-Peritoneum, A-Ascites, I-Invasion, M1/Adv.-Metastasis/Advanced, 
      Bx- Biopsy, Cy-Cytology,  Compl-Complication, 
      PGC/OGJ- Proximal gastric /Oesophago-gastric junction carcinoma  
* Liver & Peritoneum in 4, Peritoneum & Ascites in 3, Liver, Peritoneum & Ascites in 1. 
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        Laparoscopic examination was judged to be complete in all patients. 
All  the  patients  tolerated  and  recovered  well  from  the  procedure. 
Laparoscopic diagnosis and the outcome are shown in the following Table-1. 
In 37 (61.6%) patients, previously unrecognized local and distant spread of 
tumor were found by laparoscopy and confirmed by biopsy in 6 patients 
(16.2%). 
           Most of the occult metastasis were multiple and varied in size 
(1 to 15 mms). They were commonly seen on the liver (17 patients, 28.3%) 
and peritoneal  (12 patients,  20%) surfaces.  Liver  metastatic  lesions  were 
seen in 2 of 21 patients in PGC, 4 of 18 patients in pancreatic malignancy, 4 
of 10 patients in liver cancers and 7 of 11 patients in gallbladder malignancy. 
Peritoneal  deposits  were  seen   in  5  of  21  patients  in  PGC,  4  of  18  in 
pancreatic malignancy and 3 of 11 patients in gallbladder malignancy. In 6 
of  10  patients  with  hepatocellular  carcinoma  and  2  of  18  patients  in 
pancreatic malignancy showed cirrhosis. Minimal ascites was seen in 4 of 21 
patients with PGC and in one patient with pancreatic malignancy. Adjacent 
structure invasion and enlarged regional lymphnodes were seen in 9 of 21 
17
Fig: 5 Port Sites
                                       Fig: 6 Liver secondaries with cirrhosis
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Fig: 7 Oesophago-gastric carcinoma with liver secondaries
Fig: 8 Omental deposits
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Fig: 9  Minimal ascites
Fig: 10 Parietal wall secondaries 
20
Fig:11 Gall bladder carcinoma
Fig: 12 Hepatocellular carcinoma
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Fig: 13 Pancreatic carcinoma with liver secondaries
Fig: 14 Laparoscopic-guided biopsy
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patients in PGC and 2 of 11 patients in gallbladder malignancy [see figure – 
8  to  16].  All  the  guided-biopsy  (6  patients,  16.2%)  were  positive  for 
metastasis  [see figure – 16].  Ascites  /  peritoneal  lavage was taken in 15 
(40.5%) patients of which only 4 (26.6%) patients showed positive cytology. 
Incurable disease was detected in 37 of 60(61.6%) patients by laparoscopy.  
Table 2: Laparotomy.
Organ No(%)
60
For
Laparotomy
23(38.3%)
L
-
P
-
A
-
I
8
Surgery
15 
(25%)
Total 
M1/Adv
45 (75%)
Avoid 
laparotomy
37 (61.6%)
1. PGC/OG 21(35) 11 - - - 3 8(72.7) 13(61.9) 10(47.6)
2. Panc. 18(30) 10 - - - 3 7(70) 11(61.1) 8(44.4)
3. Liver 10(16.6) - - - - - - 10(100) 10(100)
4. Gallbl. 11(18.3) 2 - - - 2 2(100) 9(81.8) 9(81.8)
# L-Liver, P-Peritoneum, A-Ascites, I-Invasion, M1/Adv.- Metastasis/Advanced,
       PGC/OGJ- Proximal gastric / Oesophago-gastric junction carcinoma.   
         The rest 23 (38.3%) patients underwent laparotomy and found to have 
advanced diseases in 3 of 11 patients with PGC and 3 of 10 patients with 
pancreatic malignancy and 2 of 2 in gallbladder cancer as shown in Table-2. 
These patients had large bulky lesions with infiltration and enlarged, fixed
regional  lymphnodes.Definitive surgery  was  done  in  the  remaining  15 
(65.2%) patients ( 8 Total gastrectomy with Roux-en-y reconstruction,
7 Whipples procedure ) depending on organ of involvement and 2 palliative 
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segment-III bilioenteric anastomosis. 
         Complications were seen in 6 of 37(16.2%) patients and these includes 
basal atelectasis in 2(5.4%) patients, port-site infection in 2(5.4%) patients, 
prolonged  ileus  and  urinary  retention  in  one  each  (2.7%)  as  shown  in 
Tables – 1 & 8. There was no mortality in the present study. Patients were 
either referred or discharged between 2 to 10 days, resulting in an average 
postoperative  hospital  stay  of  2  days  for  laparoscopy  and  8  days  for 
laparotomy as shown in Table - 9.
            Laparoscopic examination indicated resectablity of tumor in 23 of 60 
(38.3%) patients  and the surgery was accomplished in 15 of  23 (65.2%) 
patients as shown in Table - 10. In the remaining 8 of 23 (34.7%) patients, 
local spread of the disease, unappreciated at laparoscopy precluded surgery.
           The ‘diagnostic accuracy’ of laparoscopy in the present study can be 
calculated as 82.2%(37 of 45 patients). Laparoscopic assessment of 
unresectable tumor proved consistently correct. The assessed accuracy of 
resectable disease was 65.2% (15 of 23 patients). The overall resectablity 
rate in the present study was 25% (15 of 60 patients) as shown in Tables – 2, 
10 & 13. All laparoscopically targeted biopsy were positive (6 of 6 patients) 
with 100% specificity.Cytological examinations of the ascitic /  lavage fluid 
were performed in 15 of 37 patients in which only 4(26.6%) patients showed 
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positive cytology as shown in Table - 7.
        Pretreatment laparoscopy had the sensitivity of 84.9%, specificity of 
100%,  positive-predictive  value  of  100%,  negative-predictive  value  of 
65.2% and an overall accuracy of 82.2% for detection of occult metastases 
and  locally  advanced  diseases.  Laparoscopy  disclosed  otherwise 
unrecognized spread (‘yield’) in 37 (61.6%) patients who were thus spared 
the burden and the risk of laparotomy as shown in Tables – 11 & 13. This 
guided to alter the course of therapy in these patients.
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5. PROFORMA
NAME:                                                        AGE:    years  SEX: male/female
ADDRESS:                                                 I.P.NO:                         SGE.NO: 
                                                                     OCCUPATION:
CLINICAL FEATURES:
DIAGNOSIS: ORGAN-                               CLINICAL STAGE-
IMAGING: USG / CT-scan / MRI- scan
    Liver-    , Peritoneum-    , Ascites-   , Invasion-   .
LAPAROSCOPY: Pneumoperitoneum-    Open / Closed 
                                Port- 1 / 2 / 3 
                                Biopsy / Cytology.
    Liver-   , Peritoneum-    , Ascites-   , Invasion-   .                  
OTHERS PROCEDURES:
HPE / CYTOLOGY REPORT:
POSTOPERATIVE COMPLICATIONS:    Major- 3 / 4 / 5 ;
                                                                           Minor- 1 / 2 ;
HOSPITAL STAY:          DAYS
FOLLOW-UP:
OTHERS REMARKS:
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6.   DISCUSSION WITH ANALYTICAL DATA
Age and sex incidence:
         
          In the present study the youngest patient was 35 years and the oldest 77 
years. Majority of the diseases were seen in the forth and fifth decades. The 
mean age being 53.2 years. Among 60 patients, 40 males and 20 females were 
seen in the present study while in the study by Molloy57 et al and Lehnert48 et al 
more than 2/3rd were males as shown in Table-3 and Fig.15 & 16. 
       Table 3: Demography
S.no. Study Total Male (%) Female(%)
1. Present study 60 40(66.6) 20(33.3)
2. Molloy57 et al,’94 244 165(67.6) 79(32.3)
3. Lehnert48 et  
al,’02
120 78(65) 42(35)
           
Fig.15 Sex incidence
Male 40 67%
Female 20 
33%
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           In the present study, malignant growth were seen involving proximal 
stomach in 35%(21), pancreas in 30%(18), liver in 16.6%(10) and gallbladder 
in 18.3%(11) of patients as shown in Table-4 and Fig.17.
Table 4: Types of organ tumors
S.no. Study Total PGC/OGJ 
(%)
Pancreas
(%)
Liver
(%)
Gallbladder
(%)
1. Present 
study
60 21(35) 18(30) 10(16.6) 11(18.3)
2. Arnold2
 et al,’99
89 49(55) 33(37) - -
3. van 
Dijkum78,79
et al,’97
226 - 118(50.6) 23(9.8) -
* PGC/OGJ- Proximal gastric / Oesophago-gastric junction carcinoma.  
           In comparison with Arnold2 et al study in which 55% were proximal 
stomach, 37% were pancreas and in van Dijkum78,  79 et al study 50.6% were 
pancreas and 9.8% were liver lesions. 
Fig.17 Types of organ tumours
Liver 10 17%
Pancreas 18 
30%PGC 21 35%
Gallbladder 11 
18%
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Occult metastases / Advanced diseases:
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Fig.18  Distribution of occult metastases and advanced disease
Laparoscopy
Laparotomy
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          In  the  present  study,  laparoscopy  identified  occult  metastases  in 
61.6%(37) in which liver lesions were seen in 23 patients, peritoneal deposits in 
12 patients, liver and peritoneal deposits in 4 patients, peritoneal deposits and 
ascites in 3 patients,  cirrhosis in 8 patients,  all  three in 2 patients,  adjacent  
organ invasion in 11 patients and ascites in 5 patients as shown in Table-5 and  
Fig.18 & 19.  
        In comparison with Kriplani & Kapur46 study, laparoscopy detected occult 
metastases in 32.5% of patients, in Warshaw82 et al and Yano87  et al studies, 
35% and 53% of patients respectively.
       However laparotomy revealed an additional 13.3% (8 of 60) of patients  
having advanced diseases in the present study, in which 8 patients had locally 
invasive lesions. In the studies by Kriplani & Kapur46, Warshaw82 et al, Arnold2 
et al  and Yano87 et al, an additional lesions detected by laparotomy were 7.5%, 
7.5%, 10.1% and 6.25% respectively.
Table 5: Occult metastases and locally advanced diseases
S.no. Study T Laparoscopy For
Laparotomy
Laparotomy Total 
M1/Adv(%)
31
L P A I Tot.(%) L P A I Tot.(%)
1. Present  
study
6
0
2
3
1
2
5 11 37(61.6) 23(38.3) - - - 8 8(13.3) 45(75)
2. Kriplani  
&Kapur
46,47,’91
4
0
5 3 - 5 13(32.5) 27 - - - 3 3(7.5) 16(40)
3. Arnold2
 et al,’99
8
9
1
2
9 - - 21(23.5) 68 5 4 - - 9(10.1) 30(33.7)
4. Warshaw82 
et al,’86
4
0
6 7 1 - 14(35) 26 3 - - - 3(7.5) 17(42.5)
5. Yano87
 et al,’00
3
2
2 1
3
- 2 17(53) 15 - 2 - - 2(6.25) 19(59.3)
# L-Liver, P-Peritoneum, A-Ascites, I-Invasion, M1/Adv.- Metastasis/Advanced.
         The total number of patients with metastases / advanced diseases were 
71.6%(43), 40%,33.7%, 42.5% and 59.3% in the present, Kriplani & Kapur46, 
Arnold2 et al, Warshaw82 et al and Yano87 et al studies respectively.
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Fig.19 Laparoscopic distribution of the 
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         The distribution of the total metastases / advanced lesions were 61.9% 
(13  of  21)  in  proximal  stomach,  61.1%  (11  of  18)  in  pancreas,  100% 
(10 of 10) in liver and 100% (11 of 11) in gallbladder cancers in the present 
study as shown in Table-6 and Fig.20.
Table 6: Distribution of  total occult metastases / advanced diseases
S.n
o.
Study Total
(%)
PGC/OGJ
(%)
Pancreas
(%)
Liver
(%)
Gallbladder 
(%)
1. Present 
stud
y
43 of 60
(71.6)
13 of 21
(61.9)
11 of 18
(61.1)
10 of 10
(100)
9 of 11
(81.8)
2. Arnold2
 et al,’99
30 of 89
(33.7)
14 of 49
(28.5)
15 of 33
(45.4)
- -
3. van 
Dijkum
78,79
 et al,’97
47 of 
226
(20.7)
- 20 of 118
(16.9)
10 of 23
(43.4)
9 of 21(42.8)
* PGC/OGJ- Proximal gastric / Oesophago-gastric junction carcinoma
         In comparison, in the study by Arnold2 et al inoperable diseases were seen 
in 28.5% in proximal stomach and 45.4% in pancreas malignancies, while in 
study by van Dijkum78, 79 et al they were 16.9% in pancreas, 43.4% in liver and 
34
42.8% in gallbladder carcinomas.
  Tissue study:
             In the present study, laparoscopic-guided biopsy were taken in  16.2% 
(6 of 37) of patients and all were positive for malignancy as shown in 
Table 7: Tissue study
S.no Study Total Biopsy Cytology
Taken
(%)
Positive
(%)
Taken
(%)
Positive
(%)
1. Present study 37 6(16.2) 6(100) 15(40.5) 4(26.6)
2. Kriplani  
&Kapur46,47,’91
40 11(27.5) 11(100) - -
3. Yano87 et al,’00 32 10(31.25) 10(100) 27(84.3) 14(51.8)
4. Warshaw82
 et al,’86
40 14(35) 14(100) - -
Table-7. In comparison, by Kriplani & Kapur46, Yano87 et al and Warshaw82 et al 
studies, biopsy were taken in 27.5%, 31.25% and 35% of patients espectively 
and all were positive.             
             Peritoneal fluid / lavage for cytology were taken in 40.5% (15 of 37)  
patients of which only 26.6% (6) were positive for malignancy. In the study by 
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Yano87 et al, fluid was taken in 84.3% of patients and 51.8% showed positive 
results.
Complications:
  
             In the present study, 61.6% (37) of patients had laparoscopy only and  
additional 38.3% (23) had both laparoscopy and laparotomy. Complications in 
‘laparoscopy only’ group were seen in 16.2% (6) patients.  They were basal 
atelectasis in 5.4% (2) patients, port-site infections in 5.4% (2) patients, urinary 
retention and ileus in 2.7% (1) each as shown in Table-8. 
Table 8: Complications
S.no Study Total Major(%) Minor(%)
1. Present study 6/37(16.2) 2(5.4) 4(10.8)
2. Luketich52 et al,’97 9/26(33.7) 1(3) 8(30.7)
3. van Dijkum 78,79 et al,’99 25/420(5.9) 8(1.9) 17(4)
          In the studies by Luketich52 et al and van Dijkum78, 79 et al complications 
were seen in 33.7% and 5.9% of the patients respectively.
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Hospital stay:
           In the present study, among the patients with unresectable diseases, the 
average number of postoperative in-patient stay was 2 days for ‘laparoscopy 
only’ group and 8 days for laparotomy patients as shown in Table-9.
 Table 9: Hospital stay( Days)
S.no Study Laparoscopy Laparotomy
1. Present study 2 8
2. Ramshaw65 et  
al,’99
1.5 5.6
 
 Ramshaw65 et  al  in  their  study  found  the  hospital  stay  of  1.5  days  for 
laparoscopy and 5.6 days for laparotomy.
Resectability:
          In the present study, the ability of the laparoscopy to find the resectability 
were 38.3% (23 of 60) and for the laparotomy were 65.2%   
(15 of 23) as shown in Table-10.
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Table 10: Resectability
S.n
o
Study Total Laparoscopy Laparotomy Without 
Laparoscopy
No. % No. % %
1. Present study 60 23 38.3 15 65.2 25
2. Kriplani  
&Kapur46,47,’91
40 24 60 20 83.3 50
3. Conlon17,18 et  
al,’96
115 74 64.3 61 82.4 53
4. Yano87 et al,’00 32 15 46.9 13 86.7 40
            In comparison, the resectability rate were 60% and 83.3% by Kriplani  
& Kapur46, 64.3% and 82.4% by Conlon16, 17,18 et al, 46.9% and 86.7% by Yano87 
et al studies respectively.
Avoided laparotomy:
            Laparoscopy detected occult metastases / advanced lesions in 
61.6%  (37)  imaging-negative  patients  and  unnecessary  laparotomy  were 
avoided in these patients in the present study as shown in Table-11.
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             Table 11: Avoided laparotomy
S.no. Study Total No. %
1. Present study 60 37 61.6
2. Kriplani &Kapur46,47,’91 40 16 40
3. Arnold2 et al,’99 89 21 23.5
4. Conlon et al,’02 144 52 36
5. van Dijkum78,79 et al,’99 420 88 21
          
         In the studies by Kriplani & Kapur46, Arnold2 et al, Conlon16, 17,18 et al and 
van Dijkum78, 79 et al, laparotomy were avoided in 40%, 23.5%, 36% and 21% 
of patients respectively. 
Distribution of avoidance of laparotomy
          The distribution of avoidance of laparotomy were 47.6% (10 of 21) in  
proximal  stomach,  44.4%  (8 of 18)  in  pancreas,  100%  (10  of  10)  in  liver 
and 81.8% (9 of 11) in gallbladder cancers in the present study as shown in 
Table-12 and Fig.21.          
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Table 12: Distribution of avoidance of laparotomy
S.
n
o.
Study Total
%(no.)
PGC/OGJ 
%(no.)
Pancreas 
%(no.)
Liver   %
(no.)
Gallbladder %
(no.)
1. Present  
study
61.6
(37 of 60)
47.6
(10 of 21)
44.4
(8 of 18)
100
(10 of 10)
81.8
(9 of 11)
2. Arnold2 
et al,’99
23.5
(21 of 89)
18.3
(9 of 49)
33.3
(11 of 33)
- -
3. van 
Dijkum78,79
 et al,’99
20
(84 of 420)
20 40 35 40
         In Arnold2  et  al  study the avoidance of laparotomy were 18.3% in 
proximal  stomach  and 33.3%  in  pancreas  cancers,  while  in van Dijkum78, 79 
et al study they were 20% in proximal stomach, 40% in pancreas,  35% in  liver
 and 40% in gallbladder cancers.
10 11
8 10
10 0
9 2
0 5 10 15 20 25
PGC
Pancreas
Liver
Gallbladder
Fig.21 Distribution of avoidance of laparotomy
Laparoscopy
Laparotomy
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Sensitivity, Specificity, Predictive value and Accuracy:
          In the present study, the sensitivity and specificity were 84.9% and 100% 
respectively as shown in Table-13, while in the study by Arnold2 et al they were 
60%  and  92%.  The  negative  predictive  value  were  65.2%,  the  positive 
predictive value were 100% and the accuracy were 82.2% in the present study 
while in the study by Yano87 et al they were 89%, 100% and 94% respectively.
 Table 13: Sensitivity, Specificity, Predictive value and Accuracy 
S.
n
o
Study No. Sensitivity
%
Specificity
%
Negative 
predictive 
value- %
Positive 
predictive 
value-%
Accuracy
%
1. Present 
study
60 87.7 100 73.9 100 86
2. Arnold2 
et al,’99
89 60 92 - - -
3. Yano87
 et al,’00
32 - - 89 100 94
            Upper intra-abdominal malignancy has been marked by a relatively low 
rate of resectability (23 to 53%) and a generally carries poor prognosis. Results 
of palliative surgery are also disappointing, while morbidity and mortality also 
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remains high. 
           Large primary (>2 to 3cms.), lymphadenopathy, hepatic and pelvic 
deposits can be detected preoperatively by conventional imaging (i.e. USG, CT, 
MRI).  However,  occult  metastases  and  local  invasion,  often  found  only  at 
laparoscopy and laparotomy in ordinary circumstances, remains the frequent 
causes for unresectability (32 to 65%).
           In this study, using the technique described, we found that a fairly  
accurate assessment of the extent of the disease can be made by laparoscopy in 
a majority of the patients. By selecting appropriate patients for operation, solely 
on the basis of  pretreatment laparoscopic evaluation, the resectability rate in 
the present study were 65.2%, an appreciable improvement when compared 
with  rates  of  approximately  25  to  53% when  patients  are  selected  without 
pretreatment  laparoscopy  (i.e.imaging).  Thus,  pretreatment  laparoscopy  can 
alter therapy in a large percentage (61.6%) of patients with intra-abdominal  
malignancy.
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7. REVIEW OF LITERATURE
          
           Jacobaeus37 coined the term ‘Laparoscopy’ in 1911 and Kelling45 
performed the first ‘Coelioskopie’ in the dog using cystoscope in 1923.The use 
of laparoscopy in the staging of cancer was described by Bernhein7 in 1911. 
Fervers27  supported  the  concept  of  creating  pneumoperitoneum  in  1933. 
Veress80 developed  the  spring-loaded  needle  for  safe  pneumoperitoneum in 
1938.  It  was  Cuscheri19,  20 who popularized its  use in  evaluating abdominal 
malignancy in 1970’s.
           The  laparoscopy  technique  is  universally  same,  using  either  
carbondioxide  pneumoperitoneum  or  abdominal-lift  devices,  done  under 
general  or  local  anesthesia.  In  the  post-surgical  abdomen  and  in  suspected 
adhesions  ‘open  (Hasson)  method’  were  applied  for  the  insertion  of  the 
cannula.  Microlaparoscopic  technique  using  5mm,  3mm,  2mm  laparoscope 
having O° or 30° angle telescopes were also described, using single umbilical 
port  in  most  of  the  cases.  Additional  ports   in  the  right  and/or  left  
hypochondrium may be required for  the instruments used for retraction and 
biopsy [see figure – 14].
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        Greene et al1, 63 in the ‘SAGES manual’ and Conlon16, 17 et al description of 
‘multiport extended laparoscopy’ stressed the importance and the methodology 
of  the thorough abdominal,  pelvic  and lesser-sac evaluation.  These includes 
general  preoperative  preparations,  careful  Veress-needle  insertion,  CO2 
insufflation and pressure maintainance between 8 to  10mmHg, ‘head-down’ 
during trocar insertion and pelvic evaluation, ‘head-up’ during upper abdominal 
screening.  With  two  additional  ports  instrumentation  ‘lesser-sac’  can  be 
evaluated  through  a  small  opening  in  the  gastro-colic  or  gastro-hepatic 
omentum [see figure – 22 & 23 ] .The order of inspection includes trocar sites  
and  underlying  tissue,  visible  surfaces  of  liver,  diaphragm,  distal  stomach, 
spleen, right paracolic gutter, caecum and ascending colon, pelvic organs and 
cavity, sigmoid, desending colon, omentum, small intestine and peritoneum. By 
gentle organ retraction with the additional port  instruments proximal stomach, 
oesophagogastric junction, pelvic organs and parts of small intestine and colon 
can  be  visualized.  Taking  peritoneal  fluid,  laparoscopic-guided  tissue  and 
lymph  node  biopsies  for  histological  study   [see  figure  –  14]  and  use  of 
laparoscopic ultrasound adds to the diagnostic yield.
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Fig: 22 Lesser-Sac evaluation
Fig: 23 Lesser-sac evaluation
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7.1  Gastric  malignancy 
              Possik61 et  al  reported from a cohort study of 360 patients that 
laparoscopic examination had a sensitivity of 87% for the detection of hepatic 
metastases and 83% for peritoneal dissemination. Kriplani & Kapur46, 47 found a 
comparable laparoscopic staging accuracy of 92% and predicted resectability in 
87%  of  patients.  Forse29  et  al  demonstrated  the  benefit  of  laparoscopy  in 
reducing the hospital stay of the patients with unresectable tumor. In Burke13 et 
al study of 103 patients, laparotomy was avoided in 23% of patients. Molloy57 
et al evaluated 244 patients and found prevention of ill-advised laparotomy in 
42%  of  patients.  Ribeiro66  et  al  have  demonstrated  that  laparoscopy  with 
peritoneal lavage should be obtained for detecting microscopic spread. Lowy51 
et  al  demonstrated  that  of  16  patients  found  to  have  metastatic  disease  at 
laparoscopy, only 5% required laparotomy at a later date for palliation and 95% 
of patients were spared unnecessary laparotomy. D’ugo24 et al report on a series 
of 100 patients, wherein distant metastases was found in 21 patients and 58 
patients had different stage of disease on laparoscopy. Conlon16, 17 et al report of 
92 patients wherein one third found to have unsuspected disease. Asencio3 et al 
studied  91  patients  and  concluded  that  laparoscopy  was  most  valuable  in 
metastatic disease with 40% were spared unnecessary laparotomies.
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  7.2   Pancreatic  malignancy
          Fernandez-Del Castillo26 et al found that unsuspected abdominal spread 
was identified at  laparoscopy in 24% of patients  and addition  of  peritoneal 
lavage,  laparoscopic  sonography  may  increase  the  yield.  Merchant55 et  al 
studied 228 patients and found that 52% of the positive cytology patients had 
unresectable disease. Minnard56 et al study of 90 patients, 46% were found to be 
unresectable.   John41  et  al  demonstrated  from  40  patients  that  staging 
laparoscopy is essential in the detection of occult intra-abdominal metastases 
and  LUS improves  the  accuracy.  Espat25  et  al  examined  155  patients  with 
unresectable disease and identified only 3 patients  required surgical  bypass. 
Bemelman7 et  al  study  of  73  patients  and  found  60%  were  unresectable. 
Warshaw82 et al found that the laparoscopy can change the treatment plan in 
35% of  the  40  patients.  Jimenez40 et  al  study  of  125  patients,  laparoscopy 
obviated 39(31.2%) unnecessary laparotomies.
7.3  Hepatic  malignancy
           Lo50 et al studied 91 patients and found laparoscopy avoided laparotomy 
in  63% of  patients.  Steele71 et  al  found  54% patients  were  unresectable  at 
laparoscopy. Rahusen64 et al study of 47 patients, only 23 underwent resection. 
Weitz86 et al study of 60 patients, 22% were spared laparotomy.
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7.4  Gall-bladder  malignancy
          Dagnini22 et al found metastases in 90.8%(89 of 98) of the patients by 
preoperative laparoscopy and biopsy were positive in 90% of patients. Hard 
white plaques on the gallbladder wall were noted in 30 patients. Jarnagin38 et al 
study of 100 patients supports staging laparoscopy, which correctly identified 
unresectable disease and prevented unnecessary laparotomy in one third of the 
patients. Weber84 et al study of 44 patients, the laparoscopy yield of detecting 
unresectable disease was 48%. Vollmer81 et al strongly recommends the staging 
laparoscopy.       
          
          Successful laparoscopy can be done in most cases except in extensive  
adhesions, which may cause failure. The efficacy of detecting occult metastases 
and  local  invasion  were  better  with  laparoscopy  (40  to  65%)  than  with 
ultrasound (20 to 70%) and CT-scan / MRI (38 to 94%), especially when the 
lesions  were  less-than  10  mms2,  5,10,11,15,16,21,23,31,36,38,40,54,57,69,75,76,77,79,81,84,86,87. 
Laparoscopy yields were better for the malignancy involving lower esophagus / 
cardia (38 to 42%)10,21,57, stomach (18 to 41%)2,16,31,36,87, pancreas                  (26 
to 46%)5,11,16,40,75,76,79,81, and liver(30 to 67%)23,38,75,76,84,86. Cytological studies were 
positive in 15 to 59% of the patients16,  57. When laparoscopic-guided biopsy, 
lymph node fine-needle cytology / excision were done it showed 
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malignancy in 90 to 100% of the cases10,  16,31,38. In many series the diagnostic 
laparoscopy caused tumor ‘up-staging’ (34 to 52.5%) and ‘down-staging’ (15.6 
to 30%)2,11,36,40,57, resulting in  ‘change of therapeutic plan’ in 11 to 17% of the 
patients10. Diagnostic laparoscopy helped in identifying incurable / unresectable 
disease  in  24  to  39%  of  the  patients15,  23,54,57,69,75,76,77,  thereby  avoiding 
unnecessary / nontherapuetic laparotomy in 10 to 76% of the patients ,57,78,79,86. 
Procedural complications were minimal (1 to 9%), usually port-site infection, 
basal atelectasis, ileus, urinary retention and the mortality were negligible (less 
than 1%)1,39,42,43. Thus the selective preliminary / diagnostic laparoscopy in the 
intra-abdominal malignancy helps in better tumor staging and prognostication.
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8.  SUMMARY
        
           Laparoscopy is superior (sensitivity of 84.9%,  specificity of 100%, 
positive  predictive  value  of  100%,  negative  predictive  value  of  65.2%,  an 
overall accuracy of 82.2% and yield of 61.6%) to ultrasonography, CT and MRI 
scans in identifying cirrhosis and small surface hepatic metastases           (1 to 
3cms.),  omental  and  peritoneal  deposits,  thereby  influencing  the  choice  of 
management. The limitations of the laparoscope include deposits concealed by 
the adhesions, stomach, omentum or mesentery and deep liver lesions, which 
were not accessible . Laparoscopy-guided biopsy has an advantage of safety in 
avoiding vessels, to detect and control of undue bleed.Laparoscopy makes it  
possible to perform cytological detection of free cancer cells in ascites or in 
lavage fluid. Laparoscopic inspection is better than macroscopic examination 
under open laparotomy in detection of small  deposits  due to its magnifying 
power. The complication rate were 16.2% and the ‘nil’ mortality concluded that  
laparoscopy was safe or safer than other methods in establishing the extent of  
the  diseases  and  tissue  diagnosis  under  direct  vision.  Another  benefit  of 
performing laparoscopy as  a  separate  staging procedure is  that  it  allows an 
assessment of the patient’s ability to tolerate anesthesia and surgical  trauma 
before embarking on major resection surgery.
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             Unnecessary / non-therapeutic laparotomy were avoided in 37(61.6%)  
patients with locally advanced diseases (17 patients, 28.3%) and occult deposits  
(33 patients, 55%) put together. Treatable complications like basal atelectasis (2  
patients, 5.4%), port-site infections(2 patients, 5.4%),ileus and urinary retention 
(1  patient,  2.7%)  were  seen  in  the  present  study.  There  was  no  mortality.  
Patients were either referred or discharged early (2 to 8 days) with the mean 
postoperative  hospital  stay  of  2  days.  The  resectability  rate  without 
pretreatment laparoscopy would have been only 25%. This was improved by 
pretreatment laparoscopy to 65.2% (15 of 23).
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9.   CONCLUSION
         
            Pretreatment / diagnostic laparoscopy is safe, effective and carries  
minimal  complications.  It  can  be  done  in  selective  group  of  abdominal 
malignancy to prognosticate the diseases outcome and to avoid unnecessary / 
non-therapeutic laparotomy, morbidity and mortality associated with it  and it  
also increases the rate of resectability. The laparoscopy is an important tool in 
the staging of intra-abdominal malignancy for patients with locally advanced 
disease without signs of tumor spread in imaging. It is a relatively simple, well-
tolerated  and  safe  procedure.  It  should  be  considered  in  all  patients  with 
‘imaging-based’ resectable  intra-abdominal malignancy in which laparotomy is 
planned,  either  to  establish  the  diagnosis  or  before  an  attempt  at  resective 
surgery.
            Accurate tumor staging facilitates the selection of patients for resection,  
neoadjuvant therapy and selective planning for better palliation. It differentiates 
potentially resectable localized disease from those with advanced or metastatic 
disease. Laparoscopy has a role in establishing the diagnosis in some situation 
by allowing guided biopsy of the intra / retroperitoneal masses, lymph node, 
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peritoneal  and  visceral  surface  lesions.  Laparoscopy  also  has  a  role  in  the 
surgical treatment and in palliative care such as feeding tube placement, stoma 
creation. Since it may benefit or adversely affect the survival or quality of life,  
‘Pretreatment laparoscopy’ can be used in carefully selected patients.
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10.MASTERCHART
S.No. NAME AGE SEX I.P.NO.: CLIN. FEAT DIAGNOSIS LAPAROSCOPYSURGERY COMPLICATION HPE/CYTOLOGY REMARKS
LIVER TUMOURS L  P  A  I
1 Rengan 60 M 676118 mass HCC C  –  –  – DL
2 Uthandaraman 60 M 701747 mass HCC C  –  –  – DL
3 Vijaya 35 F 618708 mass secondaries +  –  –  – DL
4 Chinnappan 77 M 635158 mass HCC C  –  –  – DL
5 Velu 48 M 639251 mass secondaries +  –  –  – DL
6 Dasarathan 60 M 663728 mass HCC C  –  –  – DL
7 Govindaswamy 62 M 606477 mass HCC C  –  –  – DL
8 Penicilliah 50 M 615687 mass secondaries +  –  –  – DL
9 Dharmalingam 55 M 616890 mass secondaries C  –  –  – DL
10 Chandra 45 F 623246 mass secondaries +  –  –  – DL
S.No. NAME AGE SEX I.P.NO.: CLIN. FEAT DIAGNOSIS LAPROSCOPY SURGERY COMPLICATION HPE/CYTOLOGY REMARKS
GALL BLADDER L P A I
1 Thulasi 50 F 619982 mass carcinoma +  –  –  – DL Cytology/Lavage
2 Prema 39 F 622414 mass carcinoma +  –  –  – DL Cytology/Lavage
3 Parvathy 68 F 679165 mass carcinoma +  +  –  – DL Cytology
4 Elumali 60 M 678684 mass carcinoma +  +  –  – DL Ileus Bx
5 Ranganayagi 53 F 694633 mass carcinoma +  –  –  – DL Cytology
6 Pichaikaran 50 M 693321 mass carcinoma +  –  –  – DL Bx
7 Sivalingam 46 M 701205 mass carcinoma +  –  –  – DL Cytology
8 Bavani 42 F 705291 mass carcinoma –  –  –  + seg iii bp
9 Devan 60 M 708928 mass carcinoma –  –  – + seg iii bp
10 Sekar 38 M 649179 mass carcinoma –  +  –  – DL Bx
11 Papathiammal 65 F 652892 mass carcinoma –  –  –  + DL Cytology/Lavage
S.No. NAME AGE SEX I.P.NO.: CLIN. FEAT DIAGNOSIS LAPROSCOPY SURGERY COMPLICATION HPE/CYTOLOGY REMARKS
PANCREAS L P A I
1 Emmanuvel 38 M 630184 jaundice, gbperiampullary –  –  –  – Whipple
2 Jeevarathinam 53 M 639270 jaundice, gbperiampullary –  –  –  – Whipple
3 Devaraj 60 M 638500 jaundice, gbperiampullary –  –  –  – Whipple
4 Sundaram 53 M 638643 jaundice, gbperiampullary –  –  –  – Whipple
5 Saroja 50 F 669777 jaundice, gbhead –  –  –  – inv
6 Murugasen 47 M 674036 jaundice, gbhead –  +  –  – DL Cytology/Lavage
7 Sushi 75 F 682175 jaundice, gbhead C+  –  –  – DL infection
8 Dhanalaxmi 56 F 684393 jaundice, gbhead –  –  –  – inv
9 Arumugam 45 M 688658 jaundice, gbperiampullary –  –  –  – Whipple
10 Suguna 52 F 682786 jaundice, gbhead –  –  –  – Whipple
11 Sekar 47 M 696784 jaundice, gbhead C+  –  –  – DL
12 Veeraswamy 70 M 697332 jaundice, gbhead –    –  – – inv
13 Muniammal 42 F 700597 jaundice, gbperiampullary –  –  –  – Whipple
14 Prakashrao 45 M 700598 jaundice, gbhead –  +  –  – DL Cytology/Lavage
15 Basha 56 M 712334 jaundice, gbhead +  –  –  – DL
16 Babu 43 M 700876 jaundice, gbhead –  +  –  – DL Bx
17 Saravanan 35 M 677433 jaundice, gbhead +  –  –  – DL
18 Jagannathan 68 M 678899 mass head –  +  +  – DL atelectasis Cytology/Lavage
S.No. NAME AGE SEX I.P.NO.: CLIN. FEAT DIAGNOSIS LAPROSCOPY SURGERY COMPLICATION HPE/CYTOLOGY REMARKS
PROXIMAL GASTRIC  / OG JUNCTION CANCER L P A I
1 Vasuki 35 F 613343 loa PGC –  –  –  – TG
2 Palanivel 53 M 615544 loa PGC –  –  –  – TG
3 Thara 35 F 619142 loa PGC +  +  +  + DL Cytology
4 Gandhimathy 45 F 629486 loa PGC +  +  +  + DL infection Cytology
5 Arulanandan 72 M 630535 loa PGC –  –  –  – TG
6 Abdulrahim 45 M 632709 loa PGC –  –  –  – inv
7 Chakrapani 71 M 639410 loa PGC –  –  –  – inv
8 Paulraj 50 M 644182 loa PGC –  +  –  + DL Bx
9 Kala 45 F 650005 loa PGC –  –  –  + DL
10 Elangaiamdan 60 M 668268 loa PGC –  –  +  + DL retention Cytology
11 Ekambaram 42 M 674106 loa PGC –  –  –  – TG
12 Angali 35 F 668330 loa PGC –  +  –  + DL Bx
13 Elumali 50 M 687223 loa PGC –  +  –  + DL atelectasis Bx
14 Rahamathullah 57 M 690657 loa, melenaPGC –  –  –  – TG
15 Arumugam 54 M 695153 loa, melenaPGC –  –  –  – TG
16 Venkatachalam 64 M 717780 loa, PGC –  –  –  – TG
17 Amali 48 F 712501 loa PGC –  –  +  + DL Cytology
18 Ramachandran 57 M 716491 loa, melenaPGC –  –  –  – TG
19 Kaliaperumal 62 M 717299 loa PGC –  –  –  – inv
20 Pachiammal 40 F 627026 loa PGC –  –  –  + DL Cytology/Lavage
21 Dasarathan 40 M 643338 loa PGC –  –  –  + DL
     LPAI- Liver, Peritoneum, Ascites, Invasion, C-Cirrhosis, DL- Diagnostic laparoscopy, seg iii bp- segment iii bypass,
          TG- Total gastrectomy, inv- invasion, Bx- Biopsy, HCC- Hepatocellular carcinoma, PGC- Proximal gastric cancer,
           OGJ- Oesophagogastric junction, loa- loss of appetite.
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